Prespecified secondary (subgroup) analysis of VESALIUS-CV: in 3627 patients with prior PCI but no prior MI, evolocumab vs placebo reduced 5-year 3-point MACE (7.0% vs 9.5%; HR 0.70) and 4-point MACE (17.9% vs 21.7%; HR 0.82) over median 4.6 years.
RCTn = 3,627
Bergmark et al. Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial